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HDL provides atheroprotection by facilitating cholesterol eﬄex from lipid-laden macrophages in the vessel wall. In vitro studies
have suggested impaired eﬄuxcapacity of HDLfollowinginﬂammatorychanges. We assessedtheimpact ofacute severe sepsisand
mild chronic inﬂammatory disease on the eﬄux capacity of HDL. We hypothesize that a more severe inﬂammatory state leads to
strongerimpaired cholesterol eﬄuxcapacity. Usinglipid-laden THP1cells and ﬁbroblastswe were ableto showthat eﬄux capacity
of HDL from both patients with severe sepsis or with Crohn’s disease (active or in remission), either isolated using density gradient
ultracentrifugation or using apoB precipitation, was not impaired. Yet plasma levels of HDL cholesterol and apoA-I were markedly
lower in patients with sepsis. Based on the current observations we conclude that inﬂammatory disease does not interfere with
the capacity of HDL to mediate cholesterol eﬄux. Our ﬁndings do not lend support to the biological relevance of HDL function
changes in vitro.
1.Introduction
High-density lipoprotein (HDL) cholesterol levels exhibit
strong inverse relations with cardiovascular disease risk [1–
3]. In the light of this, raising HDL has been a prime
target in current drug therapy. HDL exerts a variety of
antiatherogenic eﬀects [4]; it improves endothelial function,
inhibits thrombosis, and has potent antioxidative properties
as well as anti-inﬂammatory eﬀects [5–7]. Most importantly,
HDL is a key player in reverse cholesterol transport (RCT),
a process that facilitates transport of cholesterol from
peripheral tissues to the liver [8, 9]. In the course of this
process, small HDL precursors, such as lipid-poor apoA-I
and pre-β HDL, acquire free cholesterol and phospholipids
through the action of ATP binding cassette transporter
A1 (ABCA1) [10]. Maturation occurs through the action
of lecithin cholesterol acyltransferase (LCAT), and further
lipidation of these particles occurs by interaction with the
ATP-binding cassette transporter G1 (ABCG1) resulting
in the formation of α-HDL particles [11]. Finally, HDL
lipoproteins are—as described for mice—directly taken up
in the liver by scavenger-receptor-B1 (SR-B1) or HDL lipids
are transferred to apo-B-containing lipoproteins via the
action of cholesterol ester transfer protein (CETP) and
will be subsequently cleared through hepatic low-density
lipoprotein (LDL) receptors [5].
More recently, concerns have been raised that, beyond
HDL quantity, HDL quality changes may also contribute
to impaired cardiovascular disease (CVD) protection [12].
Inﬂammation is a central feature during all stages of athero-
sclerotic plaque formation with cytokines and chemokines
orchestrating the inﬂux of immune cells in disease ves-
sels [12, 13]. At the same time, cellular activation status
of local macrophages determines oxidation of subinti-
mal cholesteryl esters and plaque stability [14]. Systemic
inﬂammatory disease, such as rheumatoid arthritis, has been2 Cholesterol
associated with an increased CVD risk [15]. Patients with
active Crohn’s disease (CD) also presented with accelerated
atherogenesis [16], although a recent meta-analysis was
unable to substantiate an increased CV mortality rate in CD
[17].
Recent in vitro ﬁndings suggested that the propensity
towards CVD risk in chronic inﬂammatory disease might in
p a r tb er e l a t e dt oa ni m p a i r e dp r o t e c t i v ec a p a c i t yo fH D L
particles. It has been shown that myeloperoxidase (MPO), a
potent inﬂammatory mediator predominantly derived from
polymorphonuclearcells,canmodifyapoA-I,resultinginthe
generation of “dysfunctional” HDL particles with attenuated
capacity to mediate ABCA1-dependent cholesterol eﬄux
[18–22]. Colocalization of MPO and apoA-I in the human
plaque has fuelled the concept that MPO may also be
involved in HDL modiﬁcation in vivo [20, 23, 24].
In the present study we set out to analyse whether
systemic inﬂammatory disease, dependent upon the severity
of the disease, aﬀects the capacity of HDL to mediate
cholesterol eﬄux. HDL from patients in a mild chronic
(Crohn’s disease—CD) and acute severe inﬂammatory state
(sepsis) was tested in in vitro cell-based eﬄux systems. A
ﬁbroblast cell line, expressing only ABCA1 was used to test
the initial hypothesis that inﬂammation may speciﬁcally
aﬀect apoA-I-mediated cholesterol eﬄux. THP1 cells, a
macrophage cell line expressing ABCG1, ABCA1, and SR-
B1, were used to reﬂect total in vivo cholesterol eﬄux.
These studies may imply that quantity of HDL may be more
important for total cholesterol eﬄux than the quality of
HDL.
2. Methods
2.1. Patients. Ten patients with Crohn’s disease (CD) were
recruited at the outpatient clinic (inﬂammatory bowel
disease) at the AMC. During study visits, disease activity
was assessed using the Harvey Bradshaw index (HBI, a
research tool taking into account clinical parameters such as,
general well-being, abdominal pain, number of liquid stools
per day, abdominal mass and complications). Five patients
with HBI > 4w e r ec o n s i d e r e dt oh a v ea c t i v eC Da n dﬁ v e
patients with HBI < 4 were in remission. Additionally, we
have selected 8 patients with severe sepsis from the ICU
unit of the AMC. Sepsis was deﬁned as the presence of a
hemodynamic compromised state with temperature above
38◦C and CRP levels above 50mg/L. Additionally 5 healthy
controls were recruited from the general population. The
institutional review board at the AMC approved the study.
All subjects gave written informed consent.
2.2. Blood Collection and Biochemical Measurements. Blood
was collected after an overnight fast in EDTA-containing
tubes and directly placed on ice. Blood of the patients with
sepsis was collected during the admission to the hospital
disregarding the fasting status of the patient. Plasma was
isolated by centrifugation at 4◦C, 3000g for 15minutes
and stored at −80◦C for further analyses. Cholesterol and
triglycerides were analysed using a commercially available
enzymatic method (Randox, Crumlin, UK) on the Cobas
Mira autoanalyzer (Roche, Basel, Switzerland). HDLc and
LDLc were analysed by a commercial assay (WAKO, Neuss,
Germany). ApoB and apoA-I were analysed using a turbidi-
metric assay (WAKO, Neuss, Germany). Plasma C reactive
protein (CRP) was analysed with a high-sensitivity nephelo-
metric assay (Roche, Basel, Switzerland). Serum amyloid A
(SAA) concentration was analysed with a commercial avail-
able ELISA (EL10015) from Anogen (Mississauga, Canada).
HDL preparations of all patients were included in the eﬄux
studies.
2.3. HDL Isolation. HDL (d: 1.063-1.21g/mL) was isolated
by gradient ultracentrifugation in a TLR 100.4 rotor (Beck-
man Coulter, Fullerton, USA). In short, 0.9mL human
plasma was brought to density d = 1.31g/mL by addition
of KBr. UC-tubes were ﬁlled with 4ml 0.9% NaCL. 0.9ml
high density plasma was loaded underneath the NaCL using
large injection needles. HDL fraction was harvested after
centrifugation for 2h, 12◦C, 100,000rpm in a Beckman
Table top ultracentrifuge. HDL was subsequently dialysed
against PBS (0.9% NaCL, 10.9mmol/L Na2HPO4·2H2O,
1.8mmol/L NaH2 PO4·2H2O, pH 7.4; Fresenius Kabi), and
apoA-I concentration was measured and used directly in
the eﬄux experiments. Then, HDL was obtained by pre-
cipitation of the apoB-containing lipoprotein fraction with
polyethylene glycol 8000 (Sigma P-2139) as described [25].
2.4.PreparationofMPO-ModiﬁedHDL. HDLwaspurchased
from Calbiochem (cat. nr. 178452) and used for the MPO-
modiﬁcation reaction exactly as described [19]. In short,
HDL (1mg/mL apoA-I) was added to the reaction mixture
containing 50mM phosphate buﬀer, pH 7.0, containing
100μM DTPA, 100μM NaCl, 140μM hydroperoxide, 57nM
puriﬁed human MPO (BioDesign Int; cat and A63100H).
Incubations were performed at 37◦C for 1h. MPO-modiﬁed
HDL was dialyzed against PBS and used as a positive control
in the eﬄux experiments.
2.5. HDL-Mediated Cholesterol Eﬄux from Fibroblast and
THP1 Cells. Primary human ﬁbroblasts (NHDF-Ad- dermal
ﬁbroblasts; Cambrex, CC-2511) expressing human ABCA1
were grown in Hanks Balanced Salt Solution (HBSS)
medium without Ca and Mg, containing 10% FBS (GIBCO
14170-088) and 0.1% penicillin/streptomycin at 37◦Cu n d e r
5% CO2. To measure cellular cholesterol eﬄux, ﬁbroblasts
were plated and grown until 80% conﬂuency; at this point
cells were labelled for 24h, with 0.5μCi/mL 3H-cholesterol
in labeling medium (D-MEM:F-12 (1:1), Glutamax, 0.1%
penicillin/streptomycin,0.2%BSA,and30μg/mLcholesterol
in the presence or absence of 3μM LXR agonist T0901317
(Cayman Chemicals Comp.; art 71810) for ﬁbroblasts. After
labeling, eﬄux was induced by the addition of 0.5mL of
eﬄux medium, consisting of D-MEM:F-12(1:1), Gluta-
max, 0.1% P/S, 0.2% BSA, and the patients HDL, or HDL
from control subjects, isolated by apoB precipitation or
HDL isolated by ultracentrifugation at a concentration of





























































Figure 1: Plasma HDLc and ApoA-I levels in patients with CD, sepsis, and controls. Patients with CD exacerbation had decreased HDLc
levels, whereas plasma apoA-I levels were normal. In patients with sepsis, plasma HDLc levels are strongly decreased by 73% and plasma
apoA-I levels decreased by 64% as compared to controls.
∗∗P<0.001,
∗∗∗P<0.0001.
from controls, for a period of 4h. Eﬄux medium without
apoA-I was used as a negative control, and commercially
available apoA-1 at a concentration of 10μg/mL was used
as a positive control. At the end of the incubation period,
medium was expired. Cells were extracted with 2-propanol.
Both medium and cell extracts were transferred into a
vial containing scintillation ﬂuid and counts were assessed
(Packard, Tri-Carb 2900TR Liquid scintillation analyzer).
Fractional cholesterol eﬄux was obtained by measuring the
release of radio-labeled cholesterol into the medium. The
percentage eﬄux equals the counts in medium divided by
total counts in medium and cells combined, subtracted by
counts to medium without HDL (control).
THP1cells(ATCC)weregrowninRPMI1640,glutamax,
25mM HEPES, 10% FCS, and 0.1% Penn/Strep at 37◦C
under 5% CO2. One day prior to the experiment, cells were
diﬀerentiated into macrophages by addition of phorbol 12-
myristate 13-acetate (PMA: 50ng/mL; Sigma p8138) to the
cells. The eﬄux procedure was similar to that described
above for ﬁbroblasts. All experiments were performed in
triplicate on the same day in diﬀerent wells.
2.6. Statistical Analysis. A l ld a t aa r ep r e s e n t e da sm e a n
(±SD) unless stated otherwise. Statistical analysis was
performed in SPSS version 16. All diﬀerences in sepsis
and controls were analyzed using unpaired Student’s t-test
statistics. The diﬀerences in CD-active, CD-remission, and
controls were analyzed using two-way ANOVA and LSD
post hoc analysis. A P value <0.05 was considered as being
statistical signiﬁcant.
3. Results
3.1. Baseline Characteristics. The baseline characteristics of
patients with Crohn’s disease are shown in Table 1. Patients
with CD-active, reﬂecting a mild inﬂammatory state, had
10-fold higher plasma CRP levels than those with Crohn’s
disease in remission (P<0.05; Table 1). In line, patients with
CD-active had a tendency to lower plasma HDL levels (CD-
active: 1.25 ± 1.2mmol/L versus controls: 1.6 ± 0.6mmol/L;
P = 0.11; Figure 1). ApoA-I levels were similar to those
in controls. As a consequence, the HDLc/apoA-I ratio in
patients with active Crohn’s disease was not signiﬁcantly
diﬀerent (Figure 1).
In patients with sepsis, plasma CRP levels were very
high (>200mg/L). Subsequently, plasma HDLc levels were
strongly decreased (0.44 ± 0.4mmol/L; controls: 1.67 ±
0.6mmol/L; P<0.001; Figure 1). Plasma apoA-I levels4 Cholesterol
Table 1: Baseline characteristics of the subjects.
Control Crohn’s disease active Crohn’s disease remission Sepsis
Age, years 28 (3) 43 (10) 48 (15) 65 (12)
∗
Male/female 3/2 5/0 4/1 5/3
TC, mmol/L 4.7 (0.6) 4.0 (0.6) 5.12 (1.6) 1.9 (1.0)
∗∗
LDLc, mmol/L 2.57 (0.6) 2.14 (0.4) 3.06 (1.4) 1.27 (0.6)
∗∗
TG, mmol/L 1.03 (0.5) 1.25 (1.2) 1.22 (0.7) 1.70 (0.7)
CRP, mg/L 0.5 (0.2) 23.5 (27.8) 2.2 (1.8) 282 (109)
∗∗
Data are presented as mean (±SD). TC: total cholesterol; LDLc: low density lipoprotein cholesterol; HDLc: high-density lipoprotein cholesterol; TG:








































































Figure 2: Cholesterol eﬄux capacity of MPO-HDL in ﬁbroblasts and TP1 cells. HDL and MPO-HDL are used as cholesterol acceptors.
Cholesterol eﬄux potential is measured in ﬁbroblasts (white bars) and THP1 cells (black bars) under cholesterol-loaded conditions as
described. The cells are labelled for 24h, with 3H-cholesterol in the absence (a) or presence (b) of LXR agonist. Eﬄux to HDL (10μg/ m L
apoA-I) is measured during a 4h time span. Eﬄux medium without HDL is used as a negative control. Fractional cholesterol eﬄux is
determined by measuring the release of radio-labeled cholesterol into the medium. The percentage eﬄux equals the counts in medium
divided by total counts in medium and cells combined, subtracted by eﬄux to the control. Data are presented as mean ± SD;
∗∗P<0.01.
Experiments were performed in triplicate.
were 64% lower than in controls (0.5g/L versus 1.4g/L;
P<0.0001); (Figure 1), reﬂecting a strong decrease in
circulating HDL particles. The HDLc/apoA-I ratio was
markedly reduced as compared to controls (21±12mol/mol
versus 34 ± 13mol/mol; P<0.05; Figure 1). Plasma SAA
levels in patients with sepsis were signiﬁcantly higher than in
controls(sepsis:>400mg/Landcontrols:2.5(range:1.0–7.2)
mg/L). Plasma SAA levels in CD-active and CD-remission
were measured in a diﬀerent, but comparable cohort of
patients. Plasma SAA levels in CD-active was 23mg/L (range
3–148) and in CD-remission 5.4mg/L (range 1.2–69).
3.2.MPO-HDLDisplaysImpairedCholesterolEﬄuxCapacity.
We ﬁrst tested whether in vitro modulation of commercially
available human native HDL by MPO impaired the capacity
of HDL to mediate cholesterol eﬄux, measured over a 4h
time span in LXR-stimulated ﬁbroblasts to test ABCA1-
mediated eﬄux. THP1 cells were used to test total eﬄux
capacity mediated by ABG1, ABCA1 and SR-B1 and ABCA1-
mediated eﬄux under LXR agonist stimulation of ABCA1.
We have chosen to standardize the amount of HDL added
to the incubation system based on apoA-I concentration in
the HDL preparations, so that in every eﬄux experiment
comparable amounts of apoA-I are present, reﬂecting an
equal number of HDL particles. In line with expectations,
cholesterol eﬄux capacity of MPO-HDL was signiﬁcantly
decreased by 62% (P = 0.008) in ﬁbroblasts and 32%
(P = 0.01) in THP1 cells (Figure 2) under both conditions,
providing evidence that our experimental setup is viable.
3.3. Cholesterol Eﬄux Capacity of HDL from Patients with
Crohn’s Disease. HDL was isolated by ultracentrifugation as
well as by precipitation to avoid bias through the presenceCholesterol 5
of serum proteins in the PEG-precipitated HDL preparation,
whichmayinterferewiththecholesteroleﬄuxmeasurement.
Again equal amounts of apoA-I (10μg/mL) were added to
eachwellintheeﬄuxexperiment.Surprisingly,HDLisolated
by ultracentrifugation (UC-HDL) showed similar ABCA1-
mediated cholesterol eﬄux in ﬁbroblasts as compared to
controls; (Figure 3(a)). UC-HDL showed increased total
cholesterol eﬄux potential in THP1 cells (CD-active: +28%,
P<0.02 versus controls; CD-remission: +24%; P<0.01
versus controls (Figure 3(b)). PEG-HDL (10μg/mL apoA-
I), as a control, isolated from CD-active and CD-remission
patient’s plasma induced a similar ABCA1-mediated choles-
terol eﬄux in ﬁbroblasts as well as total cholesterol eﬄux
potential in THP1 cells as compared to control PEG-HDL
(Figure 3).
3.4. Cholesterol Eﬄux Capacity of HDL from Patients with
Sepsis. UC-HDLfrompatientswithsepsis,reﬂectingasevere
inﬂammatory state, showed a similar ABCA1-mediated
cholesterol eﬄux potential from cholesterol-laden ﬁbroblast
cells in the presence of a LXR agonist (Figure 4). Cholesterol
eﬄux potential from THP1 cells to UC-HDL isolated from
plasma of patients with sepsis was increased as compared
to controls (+14%, P<0.05; (Figure 4). Cholesterol
eﬄux potential of PEG-HDL in cholesterol-laden ﬁbroblast
cells was similar to controls (Figure 4), whereas cholesterol
eﬄux capacity of PEG-HDL in THP1 cells was signiﬁcantly
increased (+58%; P<0.005; Figure 4).
4. Discussion
We demonstrate that the capacity of HDL (normalized for
apoA-1 concentration) of patients with severe acute or mild
chronic inﬂammatory state, to mediate cholesterol eﬄux
from cultured cholesterol-loaded ﬁbroblasts treated with
a LXR agonist to stimulate ABCA1 expression and THP1
cells, was not decreased as compared to normolipidemic
controls. Even in patients with sepsis, suﬀering from a
severe inﬂammatory disease state, HDL eﬄux capacity is, if
anything,increasedcomparedtohealthycontrols.Thesedata
underlinethatinvitroﬁndingsregardingHDL“dysfunction”
cannot be extrapolated to an in vivo situation.
In the present study we have used two diﬀerent cell
systems to determine HDL-mediated cholesterol eﬄux
potential. Fibroblasts are known to express the ABCA-1
receptor abundantly which can be further increased by
treating the cells with a LXR agonist, whereas THP1 cells
(under lipid-laden conditions) express ABCA1, SR-B1 and
ABCG-1 and thus model lipid-laden macrophages in human
atherosclerotic plaques [26]. In line with previous reports,
we observed that HDL when exposed to MPO in a test
tube displays impaired capacity to mediate cholesterol eﬄux
from both ﬁbroblasts as well as THP1 cells, [20, 24] showing
that ABCA1-mediated cholesterol eﬄux is highly impaired
a n dt h u sp r o v i d e sv a l i d a t i o no fo u re ﬄux system. Two
diﬀerent disease models, one representing an acute, severe
inﬂammatory state (sepsis) and the other representing a
mild inﬂammatory state (Crohn’s disease), have been used in
the present study. Both disease states were characterized by
increased plasma CRP and SAA levels, as well as decreased
plasma HDLc levels, albeit not signiﬁcant in CD-active,
which is in line with HDL acting as an inverse acute
phase reactant [5]. Our original hypothesis was based
on the observation that in vitro inﬂammatory challenges
modulate HDL response to induce normal cholesterol eﬄux
from cell culture systems. We expected to see a gradual
decrease in HDL eﬄux potential with increasing severity
of inﬂammatory state. However, despite the inﬂammatory
conditions of these patients we observed a modest increase
in the eﬄux capacity of HDL, but we feel that more robust
analysis are required to further investigate this.
Thus, our data clearly indicate that impaired eﬄux
capacity of HDL in inﬂammatory disease states does not
play a signiﬁcant role in vivo. Obviously, these ﬁndings do
not exclude a decreased total eﬄux capacity, since HDLc
and apoA-I concentrations are profoundly lower in patients
with sepsis albeit not in patients with a mild inﬂammatory
state (active Crohn’s disease) [15, 27]. The eﬄux data
were obtained through controlling for apoA-I levels in the
diﬀerent HDL preparations. Plasma apoA-I levels in patients
with sepsis were 45% reduced. This means in theory that,
although HDL was more eﬃcient in accepting cholesterol
from cells, this cannot be compensated for by the strong
decrease in number of circulating HDL particles and thus an
overall decreased total eﬄux capacity.
Interestingly, we observed a slight increase in HDL
eﬄux capacity in an inﬂammatory disease state. Van Der
Westhuyzen et al. have previously shown that, besides apoA-
I, SAA is also capable of promoting cholesterol eﬄux [28].
Since we have used similar apoA-I concentrations in all our
assays and more importantly since HDL particles in the
inﬂammatory state contain an increased number of SAA
molecules, this may have been the reason for the increase
in eﬄux capacity. However, plasma SAA levels in patients
with sepsis are more than 200-fold increased as compared to
controls whereas plasma SAA levels in active Crohn’s disease
wereonlyincreased10-foldcomparedtocontrols.Therefore,
we conclude that plasma SAA levels do not contribute to the
increased cholesterol eﬄux observed in both CD-active and
sepsis.
Previous studies have suggested that smaller lipid
depleted HDL particles serve as better cholesterol acceptors
via the ABCA1-mediated eﬄux pathway [29]. Indeed, the
estimatedHDL-c/apoA-Iratiobetweencontrolsandpatients
in a severe inﬂammatory state was signiﬁcantly reduced
suggesting the presence of smaller-sized HDL particles. In
line, the average number of particles was reduced in our
study as reﬂected by the decrease in apoA-I levels. These data
lend further support to the concept that HDL quantity is
the main determinant of cholesterol eﬄux capacity under
these conditions. In contrast to our ﬁndings, Mc Gillicuddy
et al. reported that, following an acute endotoxin challenge,
several steps in the RCT pathway were disrupted [30].
Thus, in vitro exposure of macrophages to LPS signiﬁcantly
reduced ABCA1 expression thereby attenuating cholesterol
eﬄux capacity towards apoA-I. Cholesterol eﬄux acceptor



















































































Figure 3: Eﬄux potential of HDL isolated from patients with Crohn’s disease in ﬁbroblasts and THP1 cells. Cholesterol acceptor capacity
of UC-HDL (black bars) and PEG HDL (white bars) isolated from controls, and patients with active Crohn’s disease and Crohn’s disease in
remission using cholesterol-laden ﬁbroblasts and cholesterol-laden THP1 cells. Cells are labelled for 24h with 3H-cholesterol. Fibroblasts
were incubated in the presence of LXR agonist TO901317. Eﬄux to HDL (10μg/mL apoA-I) is measured during a 4h time span. Eﬄux
medium without HDL is used as a negative control. Fractional cholesterol eﬄux is determined by measuring the release of radio-labeled
cholesterol into the medium. The percentage eﬄux equals the counts in medium divided by total counts in medium and cells combined and
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Figure 4: Eﬄux potential of UC-HDL and PEG-HDL isolated from patients with sepsis in ﬁbroblasts and THP1 cells. Cholesterol acceptor
capacity of UC-HDL (black bars) and PEG-HDL (white bars) from patients with sepsis using cholesterol-laden ﬁbroblasts (and cholesterol-
laden THP1 cells). Fibroblasts were incubated in the presence of LXR agonist TO901317. Cells are labelled for 24h with 3H-cholesterol.
Eﬄux to HDL (10μg/mL apoA-I) is measured during a 4h time span. Eﬄux medium without HDL is used as a negative control. Fractional
cholesterol eﬄux is determined by measuring the release of radio-labeled cholesterol into the medium. The percentage eﬄux equals the
counts in medium divided by total counts in medium and cells combined and was corrected for counts to the medium without acceptor
HDL. Experiments were performed in triplicate. Data are presented as mean ± SD;
∗P<0.05,
∗∗P<0.01.Cholesterol 7
LPS challenge was decreased with a concomitant decrease
in plasma apoA-I level. There are several reasons that may
underlie the discrepancy with the current ﬁndings. First,
a single endotoxin challenge is not comparable to a more
sustained inﬂammation, since a wide variety of adaptation
mechanisms evolve over time [5, 31, 32]. Most importantly,
these authors failed to normalize for the decrease in apoA-
I levels after the endotoxin challenge in the cholesterol
eﬄux assay, which invariably contributes to diﬀerences in
cholesterol eﬄux. In fact, we demonstrated in septic patients
that correction for changes in apoA-I result in a normal or
even increased eﬄux acceptor capacity of HDL independent
of the HDL preparation (PEG isolated or ultracentrifugally
isolated).
4.1. Study Limitations. Our study has several limitations.
First, the patients in the present study were older compared
to the controls. Berrougui et al. have reported that par-
ticularly ABCA1-mediated cholesterol eﬄux decreased with
advancingage[33].Thisimpliesthatinpatientswemayhave
observed lower values compared to the younger controls.
However, since we ﬁnd, if anything, higher eﬄux values,
the age diﬀerence cannot have contributed to the present
observation. Second, we included only a limited number of
subjectsinourstudy.However,sinceweobserveanincreased
eﬄux in patients with an extreme inﬂammatory disease, it is
unlikely that inclusion of a larger number of subjects would
alter these ﬁndings.
4.2. Conclusion. Whereas exposure of HDL to MPO ex
vivo leads to an impaired cholesterol eﬄux, native HDL
preparations isolated from patients in mild and severe
inﬂammatory disease states retain its ability to stimulate
eﬄux. These ﬁndings do not lend support to the biological
relevance of HDL function changes observed in vitro.
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